New algorithm can predict diabetic kidney disease
Posted: 30 May 2023 | Izzy Wood (Drug Target Review) | No comments yet
Researchers from US and Hong Kong have found that a simple blood sample may help doctors catch kidney disease earlier in type 2 diabetes patients


Researchers from Sanford Burnham Prebys, US and the Chinese University of Hong Kong have developed a computational approach to predict whether a person with type 2 diabetes will develop kidney disease, a frequent and dangerous complication of diabetes. Their results, published in Nature Communications, could help doctors prevent or better manage kidney disease in people with type 2 diabetes.
“This study provides a glimpse into the powerful future of predictive diagnostics,” added co-senior author Dr Kevin Yip, Professor and Director of Bioinformatics at Sanford Burnham Prebys. “Our team has demonstrated that by combining clinical data with cutting-edge technology, it’s possible to develop computational models to help clinicians optimise the treatment of type 2 diabetes to prevent kidney disease.”
Diabetes is the leading cause of kidney failure worldwide. In the United States, 44 percent of cases of end-stage kidney disease and dialysis are due to diabetes. In Asia, this number is 50 percent.
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
“There has been significant progress developing treatments for kidney disease in people with diabetes,” says co-senior author Ronald Ma, Professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong. “However, it can be difficult to assess an individual patient’s risk for developing kidney disease based on clinical factors alone, so determining who is at greatest risk of developing diabetic kidney disease is an important clinical need.”
The new algorithm depends on measurements of a process called DNA methylation, which occurs when subtle changes accumulate in our DNA. DNA methylation can encode important information about which genes are being turned on and off, and it can be easily measured through blood tests.
“Our computational model can use methylation markers from a blood sample to predict both current kidney function and how the kidneys will function years in the future, which means it could be easily implemented alongside current methods for evaluating a patient’s risk for kidney disease,” explained Yip.
The researchers developed their model using detailed data from more than 1,200 patients with type 2 diabetes in the Hong Kong Diabetes Register. They also tested their model on a separate group of 326 Native Americans with type 2 diabetes, which helped ensure that their approach could predict kidney disease in different populations.
“This study highlights the unique strength of the Hong Kong Diabetes Register and its huge potential to fuel further discoveries to improve our understanding of diabetes and its complications,” says study co-author Juliana Chan, Professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong.
The researchers are currently working to further refine their model. They are also expanding the application of their approach to look at other questions about human health and disease—such as determining why some people with cancer do not respond well to certain treatments.
“The science is still evolving, but we are working on incorporating additional information into our model to further empower precision medicine in diabetes,” concluded Ma.
Related topics
Disease Research, DNA, Genetic Analysis, Genomics
Related conditions
Kidney disease, Type-2 diabetes
Related organisations
Sanford Burnham Prebys
Related people
Dr Kevin Yip, Juliana Chan, Ronald Ma